CM
JAZZ icon

Castleark Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Castleark Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.21M Buy
+48,740
New +$8.52M 0.3% 67
2018
Q4 		– Sell
-44,055
Closed -$7.41M – 386
2018
Q3 		$7.41M Buy
44,055
+260
+0.6% +$44.7K 0.21% 155
2018
Q2 		$7.55M Buy
43,795
+10,595
+32% +$1.73M 0.23% 137
2018
Q1 		$5.01M Buy
+33,200
New +$4.87M 0.16% 183
2015
Q3 		– Sell
-26,225
Closed -$4.62M – 386
2015
Q2 		$4.62M Sell
26,225
-30,825
-54% -$5.54M 0.12% 195
2015
Q1 		$9.86M Buy
57,050
+36,175
+173% +$6.21M 0.24% 135
2014
Q4 		$3.42M Sell
20,875
-19,681
-49% -$3.27M 0.09% 192
2014
Q3 		$5.62M Buy
+40,556
New +$6.24M 0.16% 146
2014
Q2 		– Sell
-40,556
Closed -$5.62M – 327
2014
Q1 		$5.62M Sell
40,556
-29,901
-42% -$4.5M 0.16% 146
2013
Q4 		$8.92M Buy
70,457
+67,157
+2,035% +$6.95M 0.26% 61
2013
Q3 		$530K Sell
3,300
-32,405
-91% -$2.61M 0.01% 283
2013
Q2 		$2.45M Buy
+35,705
New +$2.18M 0.08% 175

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Castleark Management's JAZZ Position: Q1 2026 in Review

Castleark Management opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2026: 48,740 shares worth $9.21M. The stake represents 0.3% of the portfolio and ranks #67 among its holdings. This is a return to the name: Castleark Management previously reported a position in JAZZ as recently as Q3 2018.

Castleark Management first reported a position in JAZZ in Q2 2013 and has held it in 12 quarters since. The position peaked at $9.86M in Q1 2015. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Castleark Management held 48,740 shares of Jazz Pharmaceuticals worth $9.21M as of Q1 2026.
  • Jazz Pharmaceuticals was a new Castleark Management position in Q1 2026.
  • Jazz Pharmaceuticals made up 0.3% of Castleark Management's portfolio in Q1 2026, its #67 holding.
  • Castleark Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 12 quarters since.
  • Castleark Management's Jazz Pharmaceuticals position peaked at $9.86M in Q1 2015.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Castleark Management's 13F filing for Q1 2026, filed 15 May 2026.